Objective: To evaluate and determine the toxicity and outcomes in patient receiving radiation (RT) alone versus concurrent chemoradiation (CRT) using cisplatin for locoregional advanced cervical cancer in Dr. Cipto Mangunkusumo Hospital (RSCM).
INTRODUCTION
Cervical cancer is the third most common cancer in women, and the seventh among all cancer , with an estimated 530,000 new cases every year and is responsible for 275,000 deaths in 2008. More than 85% of the global burden occurs in developing countries, where it accounts for 13% of all death. Overall, the mortality rate is 52% and about 88% of it occurs in developing countries. The incidence in Indonesia is about 13,762 cases and it caused approximately 7,493 deaths per year. 1 According to the Ministry of Health of the Republic Indonesia in 2005, the incidence of cancer is estimated to be in the range of 100 cases per 100,000 population or 200,000 cases annually, and more than 70% of cases came to the hospital in the advanced stage. 2 Indonesia Association of Pathologists in 2006 reported that cervical cancer was the first among 10 most frequent women cancer in Indonesia, approximately 2,459 cases 3 and the mortality rate is very high because most patients present with advanced or terminal stages. 2 During 2005-2010 in Dr. Cipto Mangunkusumo Hospital (RSCM), we obtained 2,297 cases of cervical cancer, and 66.4% arrived in advanced stages (more than stage IIB). Thus, the outcomes of treatment are often disappointing. 4 A Meta-analysis study of 4,850 patients (19 studies) found that receiving chemoradiation therapy increased progression-free survival and overall survival significantly, compared with radiation therapy alone. CRT with cisplatin regiment reduced the number of local metastases and distant metastases. 5 However, other studies showed that the outcomes of CRT in cervical cancer were still not very satisfying, numerous studies had shown it increases only 3-6% of 5-years survival rates, but the incidence of hematologic, genitourinary and gastrointestinal toxicity increased significantly in CRT groups compared with RT only groups. 6 Controversy of CRT still exists, concerning whether CRT is really feasible and effective for patients in developing countries in Asia, 7 including Indonesia, for several reasons. As regard to reasons: in Phase III studies in North America and Europe, most patients have their disease status examined by computed tomography (CT) or Magnetic Resonance Imaging (MRI), but only a limited number of patients can undergo those examination in Asia, including Indonesia, because of the socioeconomic diversity problems. In studies in the United Sates, para-aortic lymph nodes were evaluated with extra peritoneal lymphadenectomy or bipedal lymphangiography and patients who are found positive for para-aortic lymph nodes were excluded from the studies. 6, 7 These examination is not commonly used in Indonesia. Some other reason is the differences which might exist in supportive care for CRT between the developed and developing countries. In the phase III studies in the US in the 1990s, all patients are treated with low dose rate (LDR) intracavitary brachytherapy (ICBRT). 7, 8 But recently, HDR ICBRT has been performed worldwide, including in Indonesia. The combination of HDR ICBRT and CRT has been used clinically, but only few reports regarding the outcome of therapy have been published. [9] [10] [11] Therefore, the efficacy of CRT using HDR ICBRT has not been thoroughly evaluated in the clinical setting.
Pearsy et al reported a National Cancer Institute of Canada (NCIC)-sponsored trial, in which they compare cisplatin-based CRT versus radiation therapy alone inpatients with locally advanced cervical cancer. The result has not shown any significant different outcomes of CRT vs. RT alone in locally advanced cervical cancer, both in the survival of 3 years (69% vs. 66%) and 5 years (62% vs. 58%), whereas the toxicity of the chemoradiation increased 10% compared to radiation alone. 12 Similarly, a studying India by Negi et al, has show no significant difference between CRT and RT, in the evaluation complete response (60% vs. 50%), partial response (20% vs. 23.1%), progressive tumors (8% vs. 15.4%), relapse tumors (12% vs 15.4%) 13 for 3 years. Therefore, the effectiveness of CRT combined with HDR ICBRT should be evaluated carefully, especially in Indonesia, where we have different standards procedure and socioeconomic diversity problems. We expected that this study can find the outcome and toxicity effects of CRT and RT alone in patients with locoregional advanced stage cervical cancer, improve the quality of care and evaluate the treatment for locoregional advanced stage cervical cancer in the RSCM.
METHODS
This study was a Randomized Clinical Trial (RCT), with single blind method. Subjects were patients with advanced stage locoregional cervical cancer (IIB, IIIA, IIIB) who came to the outpatient gynecology oncology clinic in RSCM, and met the criteria inclusion during the period of November 2010 to
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April 2011. Sample size is based on statistical study problem, with α = 5% and β = 95%, we obtained 32 patients for our sample population. Inclusion criterias were patients newly diagnosed with cervical cancer, who have been conducted to histopathological examination and staging according to FIGO stage IIB-IIIB, with performance status score ≤ 2 based on the criteria of the Eastern Cooperative Oncology Group (ECOG) , have a normal peripheral blood examination result (Hb ≥ 10 g%, leucocyte count ≥ 5,000/mm3, platelets ≥ 150,000/ mm 3 ), liver function (SGOT < 27 U/l, ALT < 36 U/l) and kidney function (U < 50 mg/dl, creatinine 0.6-1.20 mg/dl, CCT 68-110 ml/min), willing to participate in the study and undergoing RT or CCRT in the RSCM. Tumor mass measurement is done by 3D ultrasound (Accuvix ® xQ, Medison, Seoul, Korea), and the tumor diameter was measured in three dimensions: the lateral width (W), dorsoventral thickness (T), and craniocaudal length (L). 14 External beam radiation therapy was administered using cobalt 60 teletherapy machine. A dose of 50 Gy in 25 fractions in 5 weeks was given at the rate of 2 Gy per fraction daily, for 5 days in a week. Intra cavitary brachytherapy was performed using microselectron remote controlled HDR system, Ir based, giving a dose of 21 Gy (7 Gy per weeks in 3 weeks) to point A. 15 Chemotherapy with cisplatin 30 mg/m 2 is given intravenously once a week, 6-8 hours prior to radiation, on the first day of the week for 5 series. Assessment for the response to therapy was done 3 months after the therapy is deemed completed (according RECIST criteria) by measuring the degree of tumor regression with transrectal ultrasonography, clinical examination and cytology examination. Assessment of gastrointestinal toxicities and genitourinarius is based on Radiation Therapy Oncology Group (RTOG) criterias, whereas hematologic toxicities criteria is based on a combination of Eastern Cooperative Oncology Group (ECOG) and the Gynecologic Oncology Group (GOG) criteria. Both effects were evaluated every week. The toxicities which arising were treated according to the standard management in the Division of Gynecology Oncology 
RESULTS
Between November 2010-April 2011, 32 eligible patients were enrolled for this study. They were divided into 2 groups: 16 were assigned to RT and 16 to CRT. The characteristics of demogrhapy, clinical examination, and histopathology of subjects are listed in Table 1, and Table 2 , respectively. With regard to chemotherapy, 6 cases (37.50%) received 3 cycles, 5 cases (31.25%) received 4 and 5 cycles. Meanwhile, the other 4 patients failed to receive a full 5 cycles caused by genitourinary toxicity (63.7%) and gastrointestinal toxicity (36.3%). Table 3 showed the overall acute toxicities in our study. At 3 months post-therapy, all of the cases in RT and CRT groups showed 100% complete response. 
DISCUSSION
CRT is a standard therapy for locally advanced cervical cancer in North America and in Europe, but this method has not become a standardized therapy in many Asian countries due to the differences in the patient's general status, diagnostic procedures performed, techniques of radiotherapy, tolerance to the chemotherapy and socioeconomic factors. 7 In this study, we compared the response and outcome of CRT using cisplatin 30 mg/m 2 with radiation therapy alone.
This study has advantages and limitations. One of the advantages is that the primary data directly taken through anamnesis, physical examination, gynecological examination, ultrasound and other investigations. Each case was evaluated immediately and all necessary data in accordance to objective assessment of therapeutic response was recorded. Meanwhile the limitation sare the number of samples, which is relatively small, and the fact that we have not assess the disease free survival for 1 year, recurrence rate, disease free survival and late toxicity yet. We used a total dose of 71 Gy for treatment; duration of radiotherapy, dose and method of radiation were similar among CRT and RT alone. Several studies have suggested that total length of treatment influences the efficacy of radiotherapy. [16] [17] [18] Lelieveld et al, showed that small doses of cisplatin and lower serum levels produced maximal effect 19 . Interactions leading to increased cell death, namely radiosensitization of hypoxic cells and inhibiting repair of sub lethal damage, require the presence of cisplatin prior to and after radiation therapy. Continuous infusion of the drug fulfills this requirement. The majority of randomized trials were performed by giving cisplatin few hours prior to radiation therapy. In our study, we gave cisplatin 6 -8 hours before radiotherapy.
In the evaluation on 3 months after the treatment is completed, our study showed that CRT, though tolerated well, failed to show any difference in outcome, compared with RT alone, we found that in all cases, we achieved 100% complete response, both in CRT and RT groups. Similar result was found by Kundan SC et al. After 3 months of completion of CRT, there was no statistically significant difference in response rates among RT and CRT group (p=0.235), but the survival rate at the end of 2 years were as follow: locoregional relapsefree survival is 69% vs. 61.6%, DFS 68.3% vs. 59.4%, OS 68.3% vs. 62.3% respectively among RT and CRT group. 20 Similarly, in the study by M. Garipa et al, tolerability and efficacy of the cisplatin continuous infusion during radiotherapy were studied. The tumor response, survival rate and pelvic control of 44 patients with stage IIB-IIIB cervical carcinoma were prospectively randomized into two groups: radiation alone versus radiation plus cisplatin. 21 Tumor responses were no different in the end of the treatment and 3 months after the completion of treatment. Five-year pelvic control rates were 69.4% and 63.9% (p=0.7), survival rates were 52.0% and 48.9% (p=0.7), and diseasefree survival rates were 67.5% and 58.7% (p=0.3) for the RT and the CRT groups, respectively. Although the continuous infusion of cisplatin during radiotherapy was well tolerated, this additional treatment in the form of CRT did not appear to show any improvement in pelvic control, survival rate, or disease-free survival rate. In our study, US abdomen was mainly used to evaluate para-aortic nodal status, which is an inferior modality compared to lymphangiography and CT scans, and we did not exclude patients with positive nodes. In our set up, it is difficult to carry out extensive work up like laparotomy, lymphangiography and CT scans due to financial issues and those procedures are not our routine protocol to manage advanced cervical cancer. Many patients may have had paraaortic nodes that were not detected with US abdomen, adding to our inferior results. Meta analysis by Green et al suggested that the benefit of CRT is more apparent in early stages and when disease is
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Obstet Gynecol confined to the pelvis. 22 Another factor contributing to our inferior results may be the small sample size, which may not have picked the difference of response in two treatment arms. The trial by Pearcy et al also had the smallest number of patients among all prospective randomized trials. 12 The majority of treatment failures were seen in the pelvis in the irradiated area. An analysis on the pattern of failure reveals that 29.4% of those who failed had pelvic tumor as a component of first site of failure. The study conducted by Negi et al did not show any benefit of CRT when compared to RT alone in locally advanced cervical cancer patients. 13 That could be due to more bulk of tumor stage per stage; poor nutritional status; less number of patients in both arms, not enough to pick up statistically significant small difference in outcome; the difference of dose and scheduling of radiotherapy or chemotherapy. Our results are also approximately similar to the results of 6 randomized multiinstitutional trial by the NCIC, which evaluate the patient on the third month of complete response on all group therapy. But in our study, we did not evaluate the 3 and 5 years survival rate because this study has not yet reached 1-year since the completion of therapy. Other similiarity with the NCIC study is that this study did not performa selection of patients on the suspicion of metastases in lymph nodes, but all patients, despite positive enlargement of lymph nodes which was found with ultrasound (4 patients in RT group and 3 patients in CRT group), were enrolled in this study.
Acute gastrointestinal and genitourinary toxicities were the principal adverse effects in our study. The frequency of grade 2 and 3 acute gastrointestinal toxicities and genitourinary toxicities was significantly higher in the CRT arm (p=0.000). Even though acute toxicities were found more in CRT group, they were manageable. In the majority of the patients, the GI toxicities manifested as vomiting and diarrhea, which were infrequent in RT alone group. The genitourinary toxicities manifested as nocturia happening more than 1 hour, dysuria, pelvic pain and vesica urinary spasm, which were not found in RT group. The hematology toxicity grade 2 and 3 were noted in 6 patients in CRT but were not found in RT group. Thus, there was a significant difference (p=0.002). Compared to the other randomized trials using cisplatin, we had less hematological complications, which may be due to lesser dose of cisplatin and 5-Fluorouracil that we used. The other factor leading to higher hematology toxicity in other trials is the incorporation of hydroxyurea in the treatment. The most important adverse effect with cisplatinum was emesis, but it was successfully managed by one of the 5-hydroxytryptamine antagonists. In our study, genitourinary toxicity grade 1 occurred in 7 patients (43.7%) in CRT group. No genitourinary toxicity was noted in the RT group. There was no patient death caused by concurrent cytotoxic drug therapy. Grade 3-4 gastrointestinal toxicities were higher in patients in cisplatin group in a trial by Whitney et al (8%) as compared to HU group, and there were no grade 4 nephrotoxicity. Grade 3 and 4 of other toxicities were encountered less than 2%. 8 In a study by Saibishkumar et al comparing patients receiving CRT to RT, severe acute toxicities (grade 3 ≥ RTOG criteria) were significantly higher in CRT arm (31.6 %) compared to the RT groups (11.6%), with p value < 0.001. The occurence rate of hematologic toxicity of grade 2 anemia, neutropenia and thrombocytopenia were 11.4%, 31.4% and 2.8%, respectively. 23 LT Tan et al showed that CRT using cisplatin had higher toxicity than RT alone but still had a good tolerance when given to the population of cervical cancer carried out without selection. 24 We also tried to link the OTT with the overall acute toxicity occurring in patients during therapy, and there was a significant difference between the two groups of OTT with the acute toxicities gastrointestinal, hematologic and genitourinary (p=0.003; p=0.005 and p=0.008) respectively. In this study, we found a significant differences between the two treatment groups against the cost of therapy with p-value = 0.000. Significant differences are due to the addition cost of the chemotherapy drug and the incremental cost of hospitalization because patients receiving chemotherapy require hospitalization of at least one day for one series. And also adding to the cost is drugs, functioned as an anticipation of events that will result in toxicity effects, which are given together during chemotherapy administration.
OTT is one of the prognostic factors in radio-therapy for cervical cancer. Nag S et al, recommend that the OTT should not exceed 56 days. 25 Doses of radiation in the others study protocols used 80 Gy to point A with the OTT anticipated 49 to 70 days. Some studies suggest that OTT affected the success of radiation. [18] [19] [20] This study obtained the ranges of OTT were 56-59 days with median 56.2 days in RT group, 58-70 days with median 63.5 days in CRT group. It was significantly different duration OTT with both of the arms (p=0.001).
Vol 36, No 1 January 2012
Acute toxicity of RT and CRT in cervical cancer 41
